Pharmacological analysis of human D1 and D2 dopamine receptor missense variants

Journal of Molecular Neuroscience

Volumn 34, Issue 3, 2008, Pages 211-223

  Al Fulaij, Munya A ^a   Ren, Yong ^b   Beinborn, Martin ^b   Kopin, Alan S ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Disease susceptibility; Dopamine; Dopamine receptor; GPCR; Missense variants; Polymorphisms; Therapeutic response

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE MESILATE; BUTACLAMOL; COMPLEMENTARY DNA; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM; FLUPENTIXOL; G PROTEIN COUPLED RECEPTOR; LIGAND; PERGOLIDE MESILATE; PIRIBEDIL; RECOMBINANT RECEPTOR; ROPINIROLE; ISOPROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MISSENSE MUTATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE; WILD TYPE; BINDING COMPETITION; BRAIN; BRAIN LEVEL; CELL LINE; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; SYNAPTIC TRANSMISSION;

AMINO ACID SUBSTITUTION; BINDING, COMPETITIVE; BRAIN; BRAIN CHEMISTRY; CELL LINE; DNA, COMPLEMENTARY; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 45549092254     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-007-9030-x     Document Type: Article

References (41)

1. Al-Fulaij, M. A., Ren, Y., Beinborn, M., & Kopin, A. S. (2007). Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. Journal of Pharmacology and Experimental Therapeutics, 4, 4.
2. Bach, T., Syversveen, T., Kvingedal, A. M., Krobert, K. A., Brattelid, T., Kaumann, A. J., et al. (2001). 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Archives of Pharmacology, 363, 146-160.
3. Bai, M., Quinn, S., Trivedi, S., Kifor, O., Pearce, S. H., Pollak, M. R., et al. (1996). Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. Journal of Biological Chemistry, 271, 19537-19545.
4. Beinborn, M., Lee, Y. M., McBride, E. W., Quinn, S. M., & Kopin, A. S. (1993). A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature, 362, 348-350.
5. Beinborn, M., Ren, Y., Blaker, M., Chen, C., & Kopin, A. S. (2004). Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Molecular Pharmacology, 65, 753-760.
6. Birnbaumer, M., Gilbert, S., & Rosenthal, W. (1994). An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Molecular Endocrinology, 8, 886-894.
7. Bond, R. A., & Ijzerman, A. P. (2006). Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends in Pharmacological Sciences, 27, 92-96.
8. Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., et al. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America, 95, 9608-9613.
9. Cai, G., Gurdal, H., Smith, C., Wang, H. Y., & Friedman, E. (1999). Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Molecular Pharmacology, 56, 989-996.
10. Claeysen, S., Joubert, L., Sebben, M., Bockaert, J., & Dumuis, A. (2003). A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). Journal of Biological Chemistry, 278, 699-702.
11. Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D., & Bourne, H. R. (1993). Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature, 363, 274-276.
12. Cravchik, A., Sibley, D. R., & Gejman, P. V. (1996). Functional analysis of the human D2 dopamine receptor missense variants. Journal of Biological Chemistry, 271, 26013-26017.
13. Daeffler, L., & Landry, Y. (2000). Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential. Fundamental and Clinical Pharmacology, 14, 73-87.
14. Emilien, G., Maloteaux, J. M., Geurts, M., Hoogenberg, K., & Cragg, S. (1999). Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacology and Therapeutics, 84, 133-156.
15. Feuerbach, D., Fehlmann, D., Nunn, C., Siehler, S., Langenegger, D., Bouhelal, R., et al. (2000). Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor. Neuropharmacology, 39, 1451-1462.
16. Grandy, D. K., Marchionni, M. A., Makam, H., Stofko, R. E., Alfano, M., Frothingham, L., et al. (1989). Cloning of the cDNA and gene for a human D2 dopamine receptor. Proceedings of the National Academy of Sciences of the United States of America, 86, 9762-9766.
17. Hawtin, S. R. (2006). Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor. Journal of Biological Chemistry, 281, 14604-14614.
18. Hearn, M. G., Ren, Y., McBride, E. W., Reveillaud, I., Beinborn, M., & Kopin, A. S. (2002). A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants. Proceedings of the National Academy of Sciences of the United States of America, 99, 14554-14559.
19. Hu, J., Jiang, J., Costanzi, S., Thomas, C., Yang, W., Feyen, J. H., et al. (2006). A missense mutation in the seven-transmembrane domain of the human Ca2+receptor converts a negative allosteric modulator into a positive allosteric modulator. Journal of Biological Chemistry, 281, 21558-21565.
20. Hyttel, J. (1983). SCH 23390 - the first selective dopamine D-1 antagonist. European Journal of Pharmacology, 91, 153-154.
21. Insel, P. A., Tang, C. M., Hahntow, I., & Michel, M. C. (2006). Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochimica et Biophysica Acta, 5, 5.
22. Itokawa, M., Arinami, T., Futamura, N., Hamaguchi, H., & Toru, M. (1993). A structural polymorphism of human dopamine D2 receptor, D2(Ser311->Cys). Biochemical and Biophysical Research Communications, 196, 1369-1375.
23. Izenwasser, S., & Katz, J. L. (1993). Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. European Journal of Pharmacology, 246, 39-44.
24. Kenakin, T. (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB Journal, 15, 598-611.
25. Kopin, A. S., McBride, E. W., Chen, C., Freidinger, R. M., Chen, D., Zhao, C. M., et al. (2003). Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. Proceedings of the National Academy of Sciences of the United States of America, 100, 5525-5530.
26. Leineweber, K. (2004). Beta-adrenergic receptor polymorphism in human cardiovascular disease. Annals of Medicine, 36(Suppl 1), 64-69.
27. Lin, C. W., Miller, T. R., Witte, D. G., Bianchi, B. R., Stashko, M., Manelli, A. M., et al. (1995). Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells. Molecular Pharmacology, 47, 131-139.
28. Maack, C., Cremers, B., Flesch, M., Hoper, A., Sudkamp, M., & Bohm, M. (2000). Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. British Journal of Pharmacology, 130, 1131-1139.
29. Milligan, G., & Bond, R. A. (1997). Inverse agonism and the regulation of receptor number. Trends in Pharmacological Sciences, 18, 468-474.
30. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., & Caron, M. G. (1998). Dopamine receptors: From structure to function. Physiological Reviews, 78, 189-225.
31. Oksche, A., & Rosenthal, W. (1998). The molecular basis of nephrogenic diabetes insipidus. Journal of Molecular Medicine, 76, 326-337.
32. Peeters, R. P., van der Deure, W. M., & Visser, T. J. (2006). Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. European Journal of Endocrinology, 155, 655-662.
33. Ram, A., Cao, Q., Keck, P. E., Jr., Pope, H. G., Jr., Otani, K., Addonizio, G., et al. (1995). Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. American Journal Medical Genetics, 60, 228-230.
34. Schulz, D. W., Staples, L., & Mailman, R. B. (1985). SCH23390 causes persistent antidopaminergic effects in vivo: evidence for longterm occupation of receptors. Life Sciences, 36, 1941-1948.
35. Seifert, R., & Wenzel-Seifert, K. (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild type receptors. Naunyn Schmiedebergs Archives of Pharmacology, 366, 381-416.
36. Shinyama, H., Masuzaki, H., Fang, H., & Flier, J. S. (2003). Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization. Endocrinology, 144, 1301-1314.
37. Tanaka, H., Moroi, K., Iwai, J., Takahashi, H., Ohnuma, N., Hori, S., et al. (1998). Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. Journal of Biological Chemistry, 273, 11378-11383.
38. Tiberi, M., & Caron, M. G. (1994). High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. Journal of Biological Chemistry, 269, 27925-27931.
39. Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., & Froguel, P. (2000). Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. Journal of Clinical Investigation, 106, 253-262.
40. Vallone, D., Picetti, R., & Borrelli, E. (2000). Structure and function of dopamine receptors. Neuroscience and Biobehavioral Reviews, 24, 125-132.
41. Weiner, R. I., Wetsel, W., Goldsmith, P., Martinez de la Escalera, G., Windle, J., Padula, C., et al. (1992). Gonadotropin-releasing hormone neuronal cell lines. Frontiers in Neuroendocrinology, 13, 95-119.